Lynette Caizhen Foo

Lynette Caizhen Foo

Auto-generated profile, based on publicly available information

Lynette Caizhen Foo

Department of Neurobiology, School of Medicine, Stanford University, Stanford, California 94305, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
JBJulien Bryois
Julien Bryois
DCDaniela Calini
Daniela Calini
WMWill Macnair
Will Macnair
LFLynette Foo
Lynette Foo
EUEduard Urich
Eduard Urich
DMDheeraj Malhotra
Dheeraj Malhotra

20 January 2020 in Glia
Verified
Journal Article
Closed access
PDF file
HHHelene Hirbec
Helene Hirbec
NDNicole Déglon
Nicole Déglon
LFLynette C. Foo
Lynette C. Foo
IGInbal Goshen
Inbal Goshen
JGJaime Grutzendler
Jaime Grutzendler
CECarole Escartin
Carole Escartin

10 September 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
SLSimona Lange
Simona Lange
MEMartin Ebeling
Martin Ebeling
ALAthéna Loye
Athéna Loye
FWFlorian Wanke
Florian Wanke
JSJuliane Siebourg-Polster
Juliane Siebourg-Polster
JHJan Hoeber
Jan Hoeber
Oligodendrocytes, the myelinating cells of the central nervous system (CNS), are essential for the formation of myelin sheaths and pivotal for maintaining axonal integrity and conduction. Disruption of these cells and the myelin sheaths they produce is a hallmark of demyelinating conditions like multiple sclerosis or those resulting from certain drug side effects, leading to profound neurological impairments. In this study, we created a human brain organoid comprising neurons, astrocytes, and myelinating oligodendrocytes. By integrating induced pluripotent stem cell–derived microglia, we endowed these myelinated human brain organoids (MHBOs) with immune characteristics. MHBOs with microglia (MHBOs +MG) enabled the investigation of demyelination and remyelination—a process in which myelin sheaths are regenerated—in a human context. After toxin-induced demyelination, we observed a reduction in myelin followed by subsequent self-driven remyelination. Proteomic and transcriptomic analyses provided a molecular signature of demyelination and myelin recovery indicating a central role for microglia in the remyelination process. Furthermore, the application of the pro-remyelinating compounds clemastine, XAV939, and BQ3020 further enhanced remyelination in MHBOs +MG but was ineffective in the absence of microglia. Cross-validation of our findings in mouse cerebellar slice cultures confirmed that the pro-remyelinating compounds were effective ex vivo, suggesting the translational potential of our MHBOs +MG model.

20 March 2017 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
LFLynette Caizhen Foo
Lynette Caizhen Foo
SSShilin Song
Shilin Song
SCStephen Michael Cohen
Stephen Michael Cohen
The study of adult neural cell production has concentrated on neurogenesis. The mechanisms controlling adult gliogenesis are still poorly understood. Here, we provide evidence for a homeostatic process that maintains the population of glial cells in the Drosophila adult brain. Flies lacking microRNA miR‐31a start adult life with a normal complement of glia, but transiently lose glia due to apoptosis. miR‐31a expression identifies a subset of predominantly gliogenic adult neural progenitor cells. Failure to limit expression of the predicted E3 ubiquitin ligase, Rchy1, in these cells results in glial loss. After an initial decline in young adults, glial numbers recovered due to compensatory overproduction of new glia by adult progenitor cells, indicating an unexpected plasticity of the Drosophila nervous system. Experimentally induced ablation of glia was also followed by recovery of glia over time. These studies provide evidence for a homeostatic mechanism that maintains the number of glia in the adult fly brain.

9 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
WMWill Macnair
Will Macnair
DCDaniela Calini
Daniela Calini
EAEneritz Agirre
Eneritz Agirre
JBJulien Bryois
Julien Bryois
SJSarah Jäkel
Sarah Jäkel
DMDheeraj Malhotra
Dheeraj Malhotra
The lack of understanding of the cellular and molecular basis of clinical and genetic heterogeneity in progressive multiple sclerosis (MS) has hindered the search for new effective therapies. Here, to address this gap, we analysed 632,000 single nuclei RNAseq profiles of 156 brain tissue samples, comprising white matter (WM) lesions, normal appearing WM, grey matter (GM) lesions and normal appearing GM from 54 MS patients and 26 controls. We observed the expected changes in overall neuronal and glial numbers previously described within the classical lesion subtypes. We found highly cell type-specific gene expression changes in MS tissue, with distinct differences between GM and WM areas, confirming different pathologies. However, surprisingly, we did not observe distinct gene expression signatures for the classical different WM lesion types, rather a continuum of change. This indicates that classical lesion characterization better reflects changes in cell abundance than changes in cell type gene expression, and indicates a global disease effect. Furthermore, the major biological determinants of variability in gene expression in MS WM samples relate to individual patient effects, rather than to lesion types or other metadata. We identify four subgroups of MS patients with distinct WM glial gene expression signatures and patterns of oligodendrocyte stress and/or maturation, suggestive of engagement of different pathological processes, with an additional more variable regenerative astrocyte signature. The discovery of these patterns, which were also found in an independent MS patient cohort, provides a framework to use molecular biomarkers to stratify patients for optimal therapeutic approaches for progressive MS, significantly advances our mechanistic understanding of progressive MS, and highlights the need for precision-medicine approaches to address heterogeneity among MS patients.

24 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
PGPallavi Gaur
Pallavi Gaur
JBJulien Bryois
Julien Bryois
DCDaniela Calini
Daniela Calini
LFLynette C. Foo
Lynette C. Foo
JHJeroen J. M. Hoozemans
Jeroen J. M. Hoozemans
VMVilas Menon
Vilas Menon
Alzheimer’s disease, the leading cause of dementia in the elderly, is a neurodegenerative disorder that has been studied to uncover therapeutic pathways through its molecular and cellular hallmarks. Here, we present a comprehensive investigation of cellular heterogeneity from the temporal cortex region of 40 individuals, comprising healthy donors and individuals with differing AD pathology. Using single-nucleus transcriptomic analysis of 430,271 nuclei from both gray and white matter of these individuals, we identified cell type-specific subclusters in both neuronal and glial cell types with varying degrees of association with AD pathology. We extended this analysis by performing multiplexed in situ hybridization using the CARTANA platform, capturing 155 genes in 13 individuals with differing tau pathology. We not only replicated snRNA data key findings from our spatial data analysis but also identified a set of cell type-specific genes that show selective enrichment or depletion near pathological inclusions.